Improving the Prognostic Index for Diffuse Large B-Cell Lymphoma

The International Prognostic Index (IPI) has been a powerful tool for predicting post-treatment outcomes and comparing results across clinical trials in diffuse large B-cell lymphoma (DLBCL) for more than 20 years. Given that rituximab has improved survival across all risk groups since the late 1990s, investigators have created a new prognostic model based on a retrospective analysis of 1650 newly diagnosed DLBCL patients who received induction rituximab-based chemotherapy from 2000 to 2010 at seven centers in the National …